Transient Hemolysis during Growth Hormone Therapy
スポンサーリンク
概要
- 論文の詳細を見る
Two boys with idiopathic growth hormone (GH) deficiency developed hemolysis at 2 months and 4 months, respectively, after the start of GH replacement therapy. The hemolysis was subclinical and was noticed on routine laboratory tests. Although there was no direct evidence for a causal relationship between the incident and GH therapy, no other couse was found in these 2 patients. There were no family histories suggesting hemolysis, although we did not perform tests among the family members of either patient. Despite the continuation of GH administration, the hemolysis was transient and no other adverse effects were observed during the subsequent 4 years. Such hemolytic episodes could easily be overlooked even on routine laboratory tests during GH treatment.
- 日本小児内分泌学会の論文
日本小児内分泌学会 | 論文
- 43 Common origin of the Q258X mutation in StAR gene responsible for congenital aderenal lipoid hyperplasia in Japanese
- Recent Change in the Annual Incidence of Childhood Type 2 Diabetes in the Tokyo Metropolitan Area
- A Case of Acute Lymphoblastic Leukemia with Prader-Willi Syndrome during Growth Hormone Therapy
- Characteristics of a Fulminant Onset Form of Idiopathic Type 1 Diabetes Mellitus in Japanese Children
- Different Skeletal Phenotypes in a Mother and Two Daughters with Short Stature Homeobox-Containing Haploinsufficiency